What Is Keros Therapeutics, Inc. (KROS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Keros Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $28.55. At a current market price of $11.10, 10 of 12 active valuation models identify upside potential, projecting an average implied return of +157.2%. Notably, EROIC sees the most upside at +440.9% (fair value: $60.04), while Bayesian DCF is the most conservative at -7.4% ($10.28). The spread between these extremes — +448.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About KROS?
12 of 13 models are currently active for KROS. Of these, 10 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates KROS's intrinsic value at $10.28, implying -7.4% downside from the current price. See which stocks rank higher →
How Does KROS Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, KROS ranks #169 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Keros Therapeutics, Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating KROS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is KROS a Value Trap?
CirclFi's Value Trap algorithm assigns KROS a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Keros Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Keros Therapeutics, Inc.'s fundamental quality profile registers 5.4/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +448.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every KROS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across KROS's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad